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Abstract
Many genetic causes of focal segmental glomerulosclerosis (FSGS) have been described. A paradox is that the science in the
molecular biology, which generally appears of high quality, is not mirrored by a similarly critical analysis of the renal pathology.
FSGS has been applied to such a wide range of conditions that it can reasonably be said to have no useful meaning. Attempts to
refine the term have been largely ignored. Study of 252 papers on genetic causes of FSGS found various clinical features. Many
papers took the reported diagnosis without question. Few papers reported a pathological review, almost half reported FSGS and
up to six other conditions caused by any particular gene, some reported FSGS with recognisable glomerular disorders, over 80%
did not apply the Columbia classification, and in nearly all with photomicrographs, the images were not useful for refinement of
FSGS. Some workers commented on a lack of genotype-phenotype correlation. One reason is a disregard of the principle that
scientific investigation requires an unambiguous definition of the condition studied, to allow others to replicate or refute the
findings. Genetic studies of FSGS should use a similarly rigorous approach to renal pathology to that used in molecular biology.
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Introduction
Many genetic causes of focal segmental glomerulosclerosis
(FSGS) have been described. As examples, Gast et al. [1] gave
a list of 39 genes associatedwith FSGS, Preston et al. [2] listed
48, and De Vriese et al. [3] listed 55, separated into renal
limited (21) and syndromic (34), although even this last paper
did not include some genes mentioned by others, such as
Warejko et al. [4]. This means that there are no agreed criteria
for identification of genetic causes. Also, sometimes FSGS
and steroid-resistant nephrotic syndrome have been regarded
as virtually synonymous and not differentiated [5–7]. Other
genetic causes of FSGS and/or steroid-resistant nephrotic
syndrome continue to be reported, and any paper attempting
to show a definitive list of causative genes is out of date before
publication.
The molecular biology in papers on genetic causes is pre-
sumably rigorously considered by referees and editors before
acceptance by journals. Mutation of a single base pair in an
exon of a gene is commonly reported as a significant finding,
although other genetic features such as polymorphisms are
also said to be associated with FSGS. The mere finding of
an alteration in a gene is no longer enough by itself to justify
the conclusion that the name of the gene can be added to the
list of those in which a mutation can cause FSGS. Various
conditions should be satisfied before this can be done, listed
and discussed in detail by Lovric et al. [8] and others [4, 6].
For example, detailed experimental functional studies are now
often required to support the view that any putative new ge-
netic cause of FSGS is indeed likely to be a cause [e.g. 9, 10].
A scientific paradox considered in this review is the dis-
crepancy between the rigour, precision, close control, repro-
ducibility and generally high quality of the molecular biology
and if applicable the experimental work in studies of genetic
causes of FSGS and the widespread lack of any of these prop-
erties in the selection of cases that are included in reports.
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FSGS continues to be used as a diagnosis even though virtu-
ally every paper or review accepts that the term has no useful,
definable meaning applicable to a single condition [8, 11–13].
This review concentrates on the almost universal neglect of
application of the same scientific principles to selection and
diagnosis of cases compared with the application of those
scientific principles to the molecular biological methods used
to study them. The basis of the review is 252 papers published
before September 2018, selected by the criterion that at least
one mutation or polymorphism in at least one gene was said to
be associated with at least one case of so-called FSGS, wheth-
er or not there was any further clarification of that term
[Supplement]. With such a rapidly developing topic, this se-
lection cannot be comprehensive, but any papers missed will
have little effect on the overall conclusions.
FSGS is often defined tautologously as the finding on mi-
croscopy of sclerosed areas, meaning areas that appear solid
and stain black with periodic acid-methenamine silver, that are
segmental, meaning in only part of a glomerular tuft, and
focal, meaning not in every glomerulus. There is a view that
more detailed pathological study does not contribute to under-
standing of FSGS. As examples, comments can be found that
‘At a practical therapeutic level all FSGS should be considered
equal’ [14] and ‘The etiopathogenesis of FSGS cannot be
reliably determined by light microscopy alone’ [3]. Contrary
to this view, detailed pathological investigation has shown that
cases labelled FSGS can be separated into various types, de-
pending on features such as the position of lesions within
glomeruli, the state of the kidney outside glomeruli and other
things. For example, when clinical features are also taken into
account, such as the clinical presentation and apparent renal
mass, the single term FSGS is seen to be completely inade-
quate and thoroughlymisleading for the range of conditions to
which it is applied [15–17].
Even the common attempt at refinement by the division
into primary and secondary types of FSGS is crude, imprecise
and unsatisfactory. What do these terms mean? Is FSGS
caused by a genetic disorder primary or secondary or neither?
FSGS of presumed genetic cause is often said to be not pri-
mary, and so is presumably or explicitly secondary [11, 13,
18], or is explicitly neither primary nor secondary but separate
from these [3], or is considered not secondary, and so is pre-
sumably or explicitly primary [6, 19, 20]. Bierzynska and
Saleem [6] said that patients with non-nephrotic proteinuria
and FSGS but without an underlying cause were considered to
have primary FSGS, although these do not have recurrence
after transplantation, unlike many patients with the nephrotic
syndrome and ‘primary’ FSGS. Primary FSGS associated
with the nephrotic syndrome is often thought to be caused
by something in the blood, which means that it is secondary
to whatever is circulating [6, 12, 20]. This emphasises the
inconsistent application of the term primary FSGS. Are not
all lesions secondary to some underlying cause? Do primary,
‘secondary’ and genetic forms of FSGS have any connection
with each other? If not, what is the use of the term ‘FSGS’?
The Columbia classification of FSGS was an attempt by
pathologists to reduce the ambiguity of the term FSGS by the
introduction of five types or variants, called cellular, collaps-
ing, hilar, tip and not otherwise specified (NOS) [21]. Even
though this classification has flaws, it is better than nothing in
its help to nephrologists [17]. For example, the tip variant of
FSGS has a better outcome than other variants [20, 22, 23].
Tests of reproducibility have shown that there is agreement
between pathologists in application of the Columbia classifi-
cation [24]. A study of recurrent FSGS in renal allografts
showed that four fifths of cases showed the same Columbia
variant as the original disease [25].
Selection of cases in genetic causes of focal
segmental glomerulosclerosis
There was a range of ways in which people were identified
and reported to have a genetic cause of FSGS. Most were
found by study of groups with features in common, but some
were explicitly reports of a single case or more than one case.
The distinction between a case report and a series was not
always easy to make, especially in papers about families with
an apparently inherited condition. Of the 252 papers, 199 were
regarded as series in the broadest sense, including most with
familial cases, and 53 as case reports. Familial cases were
reported in 71 papers, sporadic cases in 25 and both familial
and sporadic cases in 56, while 100 papers did not say whether
cases were familial or sporadic. There was a range of ages
studied. Only children were included in 119 papers, only
adults in 50 and both children and adults in 74, while nine
papers did not specify the age of subjects.
Clinical features of cases varied. There were three reasons
why there was difficulty in determining precise numbers of
subjects with different clinical features. At least 17 papers
included patients reported in previous studies, sometimes
without identifying which ones were included. Patients with
different features were grouped in some papers. Some papers
did not even give clinical details. The nephrotic syndromewas
a common clinical finding and a common reason for inclusion
in series, but sometimes, this was specifically only steroid-
resistant nephrotic syndrome, sometimes both steroid-
resistant and steroid-sensitive nephrotic syndrome, sometimes
unspecified nephrotic syndrome and sometimes not differen-
tiated from non-nephrotic proteinuria. Congenital nephrotic
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syndrome was sometimes included with other types of the
nephrotic syndrome, sometimes excluded, sometimes the only
clinical feature and frequently not mentioned in childhood
studies.
For the reasons given, precise numbers of these different
features cannot be determined, but at least 145 series appear to
have had the nephrotic syndrome as the main or only clinical
feature. Other clinical features, if they were mentioned, in-
cluded such things as non-nephrotic proteinuria, microscopic
haematuria, renal failure, hypertension and combinations of
features. Some of these were the main reason for inclusion
in series.
A diagnosis of FSGS was a reason for selection of cases
for study in 70 series, but this was accompanied by a variety
of clinical features, and was not necessarily the only reason
for selection. Accordingly, there is an overlap between these
70 papers and many with the nephrotic syndrome. Thirteen
papers did not specify any clinical features in those with
FSGS. Ten papers selected FSGS specifically with the ne-
phrotic syndrome but not all with the same type of nephrotic
syndrome, as described above, while 34 papers selected
FSGS with the nephrotic syndrome or other clinical fea-
tures, eight selected either FSGS or the nephrotic syndrome
and five selected FSGS with other glomerular disorders,
such as IgA nephropathy or thin glomerular basement mem-
brane disease. In some series, particularly on patients with
steroid-resistant nephrotic syndrome, some were said to
have FSGS even though a renal biopsy was reported to show
something else [26], or patients were assumed to have FSGS
[27, 28].
In 62 papers, both series and case reports, the reason for
inclusion was a variety of syndromes that included renal dis-
ease, not necessarily with the nephrotic syndrome. The most
numerous syndromes were those withWT1mutations, such as
Frasier and Denys-Drash syndromes (14 papers), various dis-
orders associated with mitochondrial DNA abnormalities,
such as MELAS syndrome and maternally inherited diabetes
mellitus and deafness (10), Alport syndrome (6), Charcot-
Marie-Tooth syndrome (5), Galloway-Mowat syndrome (3),
Pierson syndrome (3) and Schimke immunoosseous dysplasia
(3). Among the others were seven with tubular disorders, par-
ticularly Dent syndrome (3) and Bartter syndrome (2). Other
reasons for inclusion in series were, as examples, that there
was a known genetic mutation or polymorphism, or simply
that the patients had been referred for genetic testing.
There were various clinical reasons for exclusion of cases
from 44 series, particularly causes of secondary FSGS such
as reduced renal mass or obesity (28 papers, including 11
with HIV infection) or extrarenal features (8). HIV infection
was included in seven other series. The remaining series and
case reports either included patients with extrarenal features
(59) or did not mention whether there were any exclusions
on clinical grounds (142).
In the 252 papers, 91 excluded an abnormality in at least
one relevant gene, such as mutations inNPHS1 and NPHS2, a
couple of the earliest genes to be described. In theory, every
paper should have searched for all reported genetic causes
before an apparently new abnormality was described, which
may have been a coincidental and irrelevant finding.
Similarly, in theory, whenever any new cause is published,
authors of every previous paper should review their cases to
see whether that cause was missed, and was a more likely
cause or contributor to the condition. Bierzynska and Saleem
[6] warned that ‘almost all historical reports of causal variants
need to be reassessed against current reference datasets, to
filter out those that are no longer deemed causative’.
This overview shows that genetic studies of FSGS had no
consistency in the population studied. Althoughmany patients
with FSGS had steroid-resistant nephrotic syndrome, some
did not. Was the FSGS reported in anyone with steroid-
resistant nephrotic syndrome, for example, the same as the
FSGS reported in a case of congenital nephrotic syndrome,
or an adult with asymptomatic proteinuria, or a child with
Alport syndrome or someone with a tubular disorder?
The concept of phenocopies of genetic causes of FSGS or
steroid-resistant nephrotic syndrome was introduced by
Warejko et al. [4], without an explicit definition. This cannot
mean disorders which are genetic but do not affect the same
cells as ‘genuine’ genetic causes of FSGS, which often seem
to be confined to those purely affecting podocytes [8, 29, 30].
For example, one gene said to cause a phenocopy of genetic
causes of FSGS was GLA, mutated in Fabry disease, which
affects podocytes [31]. The non-phenocopy group of Warejko
et al. [4] included genes in the syndromic group of De Vries
et al. [3], such asCOQ2, INF2, LAMB2, LMX1B, SMARCAL1
and WT1, and so genes causing FSGS can affect podocytes
and cells outside the kidney. Similarly confusing is the finding
that several genetic abnormalities that cause tubular disorders
[32] have been reported to cause FSGS, such as CLCN5, mu-
tated in Dent disease 1 [33], and SLC12A1, mutated in Bartter
syndrome type 1 [34], although these are not always included
in lists of genetic causes of FSGS. Also overlooked sometimes
are mitochondrial DNA mutations reported in cases of FSGS
[e.g. 35–39], and glycogen storage diseases said to cause
FSGS [40, 41].
The diagnosis of focal segmental
glomerulosclerosis in studies
There seemed a readiness of many pathologists to apply the
term FSGS and a readiness of those doing the genetic
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studies to accept the diagnosis. In only 21 papers (8% of
252) was there a mention that there was a review of light
microscopic sections on every renal biopsy or every avail-
able biopsy or most biopsies by at least one pathologist.
This should in theory give consistency in the cases included
and excluded [e.g. 38, 42, 43]. Otherwise, the diagnosis of
FSGS in series appeared to have been taken from reports by
various pathologists. Why this is important is shown by the
finding that in nearly half of the papers, 122 out of 252
(48%), any particular gene was reported to cause not only
FSGS, but other glomerular abnormalities. This excludes
papers mentioning only global sclerosis of glomeruli as an-
other finding. Commonly reported other diagnoses were
minimal change nephropathy, mesangial proliferative glo-
merulonephritis, IgM nephropathy, membranoproliferative
glomerulonephritis, diffuse mesangial sclerosis and con-
genital nephrotic syndrome of Finnish type, but there were
many others. As examples, Chernin et al. [44] reported
FSGS and four of these other diagnoses in children with
WT1 mutations, and Sadowski et al. [45] reported FSGS
and six other diagnoses, including Alport nephropathy, in
children with NPHS2 mutations. Can genetic abnormalities
really cause multiple glomerular disorders, or is a more
likely explanation that there was inconsistency between pa-
thologists in these studies?
Sometimes, among conditions as well as FSGS that were
reported in particular mutations, unsatisfactory terms ap-
peared, such as ‘minimal unspecific glomerular changes’,
‘unclear (or no) diagnosis’, ‘mild (or minor) glomerular
changes’, ‘nonspecific tubulointerstitial nephropathy’,
‘not classifiable’, ‘unclassifiable glomerulopathy’, ‘non-
specific pathology’ and ‘no findings’. This again empha-
sises how unreliable is mere copying of reports from a va-
riety of pathologists, especially those who are not experts in
renal pathology. Also, FSGS was said to occur in glomeruli
with diagnoses such as IgA nephropathy [46], diabetic glo-
merulopathy [47], haemolytic-uraemic syndrome [48],
Alport syndrome [49] and thin glomerular basement mem-
branes [50]. Did the patients have two disorders, or were the
segmental lesions a complication of the other condition? If
they were a complication, would the diagnosis be better as,
for example, Alport syndrome with sclerosing glomerular
lesions, rather than merely FSGS?
Application of the Columbia classification would be a
test of whether a paper attempted to refine the diagnosis of
FSGS. Columbia appeared in 2004 [21], although it had
been suggested by D’Agati in 2003 [51]. Naturally, only
papers published after the classification was published
could incorporate it in their findings. The year 2005 was
arbitrarily selected as the earliest publication date when
Columbia, or various related papers, could be quoted [21,
23, 51–53]. Of 200 papers published in 2005 and after-
wards, 140 (70%) did not apply or give a reference to
Columbia or relevant papers by D’Agati, and 22 (11%)
mentioned Columbia/D’Agati but did not apply the classi-
fication. Another 24 papers (12%) did not mention
Columbia/D’Agati but included at least one term used in
Columbia, almost always just collapsing FSGS, a term
which had been introduced earlier [54] and so did not nec-
essarily indicate familiarity with Columbia or application of
it. Only 14 (7%) papers both mentioned and applied
Columbia. Incidentally, the paper that introduced the term
collapsing glomerulopathy said that it was ‘clinically, path-
ological ly, and epidemiological ly different from
noncollapsing FSGS’ [54], although this distinction has of-
ten been ignored [17].
Photomicrographs were common in papers on genetic
causes of FSGS, and were included in 86 of 252 papers
(34%). A problem is that the figures were almost always just
of one glomerulus, and an illustration of one glomerulus in
itself generally is of little value. For satisfactory interpretation
of a segmental glomerular lesion, the ideal information should
be a description of the lesion, its site within the glomerulus,
which requires the landmarks of the hilum and tubular origin to
be shown, the condition and size of the rest of the glomerulus,
the number of glomeruli affected and the condition of the rest
of the kidney [17]. Hardly any papers satisfied these require-
ments. In only 12 papers (14% of 86) could the site of a single
type of segmental lesion be identified, and this was at the
glomerular hilum in 11 of these. In most papers, 48 of 86
(56%), figures showed segmental lesions that either were at
unidentifiable sites in glomeruli or were large or at various
sites in glomeruli, meaning that they were late lesions [16].
In 17 papers (20%), there were no segmental lesions, either
because the figure was indistinct or definitely had no visible
lesion or because an abnormality affected the whole glomeru-
lus, which means it was global rather than segmental, and so
could not strictly be called FSGS on any definition. Several of
these global lesions were said to show collapsing glomerulop-
athy, which seems to be conventionally or explicitly included
in the term FSGS, even though the changes are distinctive and
are generally global, not segmental [17, 54]. In the other nine
papers (10%), segmental lesions were seen in association with
an identifiable disorder, most commonly IgA nephropathy.
No paper mentioned that the position of segmentally
sclerosed glomeruli in the cortex was analysed. Following
the work of Rich [55], FSGS is often said to affect glomeruli
in the inner/juxtamedullary cortex, although this is probably
only true in children [17]. Diffuse mesangial sclerosis ap-
pears different because this is reported to be worse in the
outer cortex [56], but only one paper appears to have inves-
tigated this [57]. In virtually all papers, study not only of
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glomeruli but of the whole kidney tissue in a biopsy sample
was unsatisfactory [17].
Why this is important
These findings on the selection, diagnosis, description and
illustration of cases show that the literature on genetic
causes of FSGS is in confusion. One reason why this is
important is because the first requirement for study of any
condition is to have a precise definition of that condition so
that as in any scientific study, other workers can investigate
and replicate or refute the original findings. At the moment,
there can be little certainty that any paper on FSGS is study-
ing the same condition as any other paper. The confused
state of genetics of FSGS contrasts sharply with the rela-
tively much more straightforward genetics of membranous
nephropathy, a diagnosis that is uncontroversial compared
with FSGS [58]. The critical scientific principles applied to
the molecular biology do not appear to have been applied to
interpretation of the pathological findings of changes called
FSGS. A suggested solution for any proposed study is that
those working on the genetics do not take a diagnosis of
FSGS at face value unless there has been a thorough review
of renal biopsy specimens by a pathologist familiar with the
latest ideas on segmental sclerosing disorders, and there is
an attempt to classify the segmental lesions. Barisoni and
others investigated concordance between pathologists in
identification of various features in renal biopsy specimens
[59]. They suggested that rather than concentration on sin-
gle features of segmental glomerular sclerosis, which gave
inconsistent concordance, better concordance would be pro-
duced by use by pathologists of ‘the totality of the histopa-
thology to arrive at a diagnosis’. This has been suggested
previously [15–17].
Another reason why this is important is related to under-
standing of the pathogenesis of segmental lesions. A few
papers reporting mitochondrial DNAmutations have shown
that the lesions in affected glomeruli are at the vascular pole
or hilum and are associated with abnormalities of arterioles
[35–37, 39]. Although this does not explain how the lesions
develop, it suggests where research could concentrate to
find out the pathogenesis. Similarly, a few papers reporting
segmental lesions in kidneys with genetic tubular disorders
and glycogen storage disorders have indicated that these
lesions may be consequences of glomerular functional over-
load following a reduction in nephron numbers [34, 40, 41].
Hardly any other papers suggested a mechanism of de-
velopment of segmental sclerosing lesions, other than vague
ideas that the lesions were due to podocyte disorders, which
would be expected to produce lesions randomly distributed
in glomeruli [17]. One paper, not included in the series of
252 papers because it avoided use of the term FSGS as a
diagnosis, was Ozaltin et al. [60] onDGKE variants causing
a glomerular microangiopathy: ‘There were also secondary
focal and segmental sclerotic glomeruli, which could be
seen in the advanced stage of any glomerulopathy’.
Although most genes said to cause FSGS are expressed in
podocytes [8, 29, 30], few have suggested how genetic ab-
normalities could cause segmental sclerosing lesions. A rare
example is Henderson et al. [61], who found that perihilar
segmental lesions, typical of glomerular overload or hyper-
perfusion or hyperfiltration or post adaptive changes [17],
were common in kidneys with ACTN4 mutations, even
though some biopsies did not seem to show significant loss
of renal mass, nor glomerular enlargement. They speculated
that podocytes with ACTN4 mutations were less mechani-
cally robust than normal podocytes, and more sensitive to
damage by normal glomerular capillary pressures. No pa-
pers analysed the distribution of segmentally sclerosed glo-
meruli in the cortex to see if genetic disorders showed the
typical childhood pattern, with juxtamedullary glomeruli
affected first [17, 55].
A more scientific approach to all cases of FSGS may
reveal more precise genotype-phenotype correlations than
are currently known. Until this is done, the study of ge-
netic causes of FSGS will remain unsatisfactory. Some
workers have expressed disillusionment with reported re-
nal biopsy findings. These include Bierzynska et al. [62],
who wrote, ‘Biopsy reports did not correlate in any sys-
tematic way with genetic results identified’ , and
Schultheiss et al. [63], whose paper was entitled ‘No ev-
idence for genotype/phenotype correlation in NPHS1 and
NPHS2 mutations’. The importance of phenotyping in ge-
netic studies, including the renal biopsy diagnosis, has
been stressed by others [45, 64]. There is the possibility
that there is no correlation between any particular genetic
abnormality and the glomerular changes it produces, but
until there is a rigorous test of this, no one will know. A
more critical approach to FSGS is necessary to reduce the
confusion about this ‘overused and misunderstood de-
scriptive phrase’ [65].
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